JP Patent

JP2015515988A — 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤

Assigned to エクセリクシス，インク． · Expires 2015-06-04 · 11y expired

What this patent protects

本発明は、ＭＥＴおよびＶＥＧＦの二重阻害剤を用いた、癌、特に去勢抵抗性前立腺癌および溶骨性骨転移の治療を対象とする。【選択図】図１

USPTO Abstract

本発明は、ＭＥＴおよびＶＥＧＦの二重阻害剤を用いた、癌、特に去勢抵抗性前立腺癌および溶骨性骨転移の治療を対象とする。【選択図】図１

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: JP2015515988A
Jurisdiction: JP
Classification: —
Expires: 2015-06-04
Drug substance claim: No
Drug product claim: No
Assignee: エクセリクシス，インク．
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.